Skip to main content
Top
Published in: Endocrine Pathology 4/2018

01-12-2018

Catecholamine-Synthesizing Enzymes in Pheochromocytoma and Extraadrenal Paraganglioma

Authors: Sachiko Konosu-Fukaya, Kei Omata, Yuta Tezuka, Yoshikiyo Ono, Yayoi Aoyama, Fumitoshi Satoh, Fumiyoshi Fujishima, Hironobu Sasano, Yasuhiro Nakamura

Published in: Endocrine Pathology | Issue 4/2018

Login to get access

Abstract

In chromaffin cells, tyrosine hydroxylase (TH), aromatic l-amino acid decarboxylase (AADC), dopamine β-hydroxylase (DBH), and phenylethanolamine N-methyltransferase (PNMT) are mainly involved in catecholamine synthesis. In this study, we evaluated the association between the status of catecholamine-synthesizing enzymes and histopathological features of pheochromocytoma and extraadrenal paraganglioma with special emphasis upon their postoperative clinical behavior. Immunohistochemical evaluation of TH, DBH, AADC, PNMT, Ki 67, and S-100 was performed in 29 pheochromocytoma and 10 extraadrenal paraganglioma and one lymph node harboring metastatic pheochromocytoma. Among these cases, metastasis was subsequently developed in three cases. Urinary normetanephrine (U-NM) levels were significantly higher in clinical metastatic cases than non-metastatic ones. Ki 67 labeling index was significantly higher in both clinical metastatic cases and the Adrenal Gland Scaled Score (PASS) score of ≧ 4 cases than PASS < 4 cases, although this score was originally used in pheochromocytoma. H-score of AADC and DBH were significantly lower in PASS ≧ 4 cases than those with < 4 cases, and in the cases associated with intratumoral necrosis (n = 4), the presence of spindle shaped tumor cells (n = 4), and large nests of cells or diffuse growth (n = 5). Lower status of intratumoral AADC could be related to poor differentiation of tumor cells in both catecholamine production and morphology and could be related to aggressive biological behavior of both pheochromocytoma and extraadrenal paraganglioma.
Literature
1.
go back to reference Isobe K, Nakai T, Yukimasa N, Nanmoku T, Takekoshi K and Nomura F (1998) Expression of mRNA coding for four catecholamine-synthesizing enzymes in human adrenal pheochromocytomas. Eur J Endocrinol 138:383–387.CrossRef Isobe K, Nakai T, Yukimasa N, Nanmoku T, Takekoshi K and Nomura F (1998) Expression of mRNA coding for four catecholamine-synthesizing enzymes in human adrenal pheochromocytomas. Eur J Endocrinol 138:383–387.CrossRef
2.
go back to reference Osinga TE, Korpershoek E, de Krijger RR, Kerstens MN, Dullaart RPF, Kema IP, van der Laan BFAM, van der Horst-Schrivers ANA, Links TP (2015) Catecholamine-Synthesizing Enzymes Are Expressed in Parasympathetic Head and Neck Paraganglioma Tissue. Neuroendocrinology 101:289–295.CrossRef Osinga TE, Korpershoek E, de Krijger RR, Kerstens MN, Dullaart RPF, Kema IP, van der Laan BFAM, van der Horst-Schrivers ANA, Links TP (2015) Catecholamine-Synthesizing Enzymes Are Expressed in Parasympathetic Head and Neck Paraganglioma Tissue. Neuroendocrinology 101:289–295.CrossRef
3.
go back to reference Meijer WG, Copray SC, Hollema H, Kema IP, Zwart N, Mantingh-Otter I, Links TP, Willemse PH, de Vries EG (2003) Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. Clin Chem 49:586–593.CrossRef Meijer WG, Copray SC, Hollema H, Kema IP, Zwart N, Mantingh-Otter I, Links TP, Willemse PH, de Vries EG (2003) Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. Clin Chem 49:586–593.CrossRef
4.
go back to reference Kimura N, Miura Y, Nagatsu I and Nagura H (1992) Catecholamine synthesizing enzymes in 70 cases of functioning and non-functioning phaeochromocytoma and extra-adrenal paraganglioma. Virchows Arch A Pathol Anat Histopathol 421:25–32.CrossRef Kimura N, Miura Y, Nagatsu I and Nagura H (1992) Catecholamine synthesizing enzymes in 70 cases of functioning and non-functioning phaeochromocytoma and extra-adrenal paraganglioma. Virchows Arch A Pathol Anat Histopathol 421:25–32.CrossRef
5.
go back to reference Kloeppel G, Lloyd R, Osamura R, Roasi J eds. (2017) Tumours of the adrenal medulla and extra-adrenal paraganglia. WHO Classification of Tumours of Endocrine Organs, 4th edn. Lyon: IARC Press; 179–195. Kloeppel G, Lloyd R, Osamura R, Roasi J eds. (2017) Tumours of the adrenal medulla and extra-adrenal paraganglia. WHO Classification of Tumours of Endocrine Organs, 4th edn. Lyon: IARC Press; 179–195.
6.
go back to reference Goldstein RE, O'Neill JA, Jr., Holcomb GW, 3rd, et al (1999) Clinical experience over 48 years with pheochromocytoma. Ann Surg 229:755–764.CrossRef Goldstein RE, O'Neill JA, Jr., Holcomb GW, 3rd, et al (1999) Clinical experience over 48 years with pheochromocytoma. Ann Surg 229:755–764.CrossRef
7.
go back to reference Edstrom Elder E, Hjelm Skog AL, Hoog A and Hamberger B (2003) The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 29:278–283.CrossRef Edstrom Elder E, Hjelm Skog AL, Hoog A and Hamberger B (2003) The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 29:278–283.CrossRef
8.
go back to reference Lowery AJ, Walsh S, McDermott EW and Prichard RS (2013) Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist 18:391–407.CrossRef Lowery AJ, Walsh S, McDermott EW and Prichard RS (2013) Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist 18:391–407.CrossRef
9.
go back to reference Tischler AS and deKrijger RR (2015) 15 YEARS OF PARAGANGLIOMA: Pathology of pheochromocytoma and paraganglioma. Endocr Relat Cancer 22:T123–T133.CrossRef Tischler AS and deKrijger RR (2015) 15 YEARS OF PARAGANGLIOMA: Pathology of pheochromocytoma and paraganglioma. Endocr Relat Cancer 22:T123–T133.CrossRef
10.
go back to reference Strong VE, Kennedy T, Al-Ahmadie H, et al (2008) Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143:759–768.CrossRef Strong VE, Kennedy T, Al-Ahmadie H, et al (2008) Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143:759–768.CrossRef
11.
go back to reference Thompson LD (2002) Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26:551–566.CrossRef Thompson LD (2002) Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26:551–566.CrossRef
12.
go back to reference Wu D, Tischler AS, Lloyd RV, et al (2009) Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol 33:99–608.CrossRef Wu D, Tischler AS, Lloyd RV, et al (2009) Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol 33:99–608.CrossRef
13.
go back to reference Achilles E, Padberg BC, Holl K, Kloppel G and Schroder S (1991) Immunocytochemistry of paragangliomas—value of staining for S-100 protein and glial fibrillary acid protein in diagnosis and prognosis. Histopathology 18:453–458.CrossRef Achilles E, Padberg BC, Holl K, Kloppel G and Schroder S (1991) Immunocytochemistry of paragangliomas—value of staining for S-100 protein and glial fibrillary acid protein in diagnosis and prognosis. Histopathology 18:453–458.CrossRef
14.
go back to reference Tavangar SM, Shojaee A, Moradi Tabriz H, et al (2010) Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma. Pathol Res Pract 206:305–309.CrossRef Tavangar SM, Shojaee A, Moradi Tabriz H, et al (2010) Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma. Pathol Res Pract 206:305–309.CrossRef
15.
go back to reference Tischler AS (2008) Pheochromocytoma: time to stamp out “malignancy”? Endocr Pathol 19:207–208.CrossRef Tischler AS (2008) Pheochromocytoma: time to stamp out “malignancy”? Endocr Pathol 19:207–208.CrossRef
16.
go back to reference Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91:4505–4509.CrossRef Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91:4505–4509.CrossRef
17.
go back to reference Feldman JM and Wells SA, Jr (1979) Adrenal-cortical function in patients with medullary carcinoma of the thyroid and pheochromocytoma. Horm Metab Res 11:567–570.CrossRef Feldman JM and Wells SA, Jr (1979) Adrenal-cortical function in patients with medullary carcinoma of the thyroid and pheochromocytoma. Horm Metab Res 11:567–570.CrossRef
18.
go back to reference Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq J, Fonseca E, Ghillani PP, Aubert B, Travagli JP, Gardet P, Parmentier C (1992) Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 15:631–642.CrossRef Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq J, Fonseca E, Ghillani PP, Aubert B, Travagli JP, Gardet P, Parmentier C (1992) Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 15:631–642.CrossRef
19.
go back to reference Huynh TT, Pacak K, Wong DL, et al (2006) Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Ann N Y Acad Sci 1073:241–252.CrossRef Huynh TT, Pacak K, Wong DL, et al (2006) Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Ann N Y Acad Sci 1073:241–252.CrossRef
20.
go back to reference Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL, McCarty KS Jr (1986) Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46:5419–5425.PubMed Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL, McCarty KS Jr (1986) Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46:5419–5425.PubMed
21.
go back to reference Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G and Plouin PF (2005) Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 90:2110–2116.CrossRef Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G and Plouin PF (2005) Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 90:2110–2116.CrossRef
22.
go back to reference Feng F, Zhu Y, Wang X, Wu YX, Zhou WL, Jin XL, Zhang RM, Sun FK, Kasoma Z, Shen ZJ (2011) Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol 185:1583–1590.CrossRef Feng F, Zhu Y, Wang X, Wu YX, Zhou WL, Jin XL, Zhang RM, Sun FK, Kasoma Z, Shen ZJ (2011) Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol 185:1583–1590.CrossRef
23.
go back to reference Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giachè V, Mannelli M. (2012) Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol. 2012: 872713.CrossRef Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giachè V, Mannelli M. (2012) Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol. 2012: 872713.CrossRef
24.
go back to reference Kimura N, Takekoshi K, Horii A, Morimoto R, Imai T, Oki Y, Saito T, Midorikawa S, Arao T, Sugisawa C, Yamada M, Otuka Y, Kurihara I, Sugano K, Nakane M, Fukuuchi A, Kitamoto T, Saito J, Nishikawa T, Naruse M (2014) Clinicopathological study of SDHB mutation-related pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer 21:L13–L16.CrossRef Kimura N, Takekoshi K, Horii A, Morimoto R, Imai T, Oki Y, Saito T, Midorikawa S, Arao T, Sugisawa C, Yamada M, Otuka Y, Kurihara I, Sugano K, Nakane M, Fukuuchi A, Kitamoto T, Saito J, Nishikawa T, Naruse M (2014) Clinicopathological study of SDHB mutation-related pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer 21:L13–L16.CrossRef
25.
go back to reference Koh JM, Ahn SH, Kim H, et al. (2017) Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One 12(11):e0187398.CrossRef Koh JM, Ahn SH, Kim H, et al. (2017) Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One 12(11):e0187398.CrossRef
26.
go back to reference Foo SH, Chan SP, Ananda V and Rajasingam V (2010) Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management. Singapore Med J 51:e89–e93.PubMed Foo SH, Chan SP, Ananda V and Rajasingam V (2010) Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management. Singapore Med J 51:e89–e93.PubMed
27.
go back to reference Proye C, Fossati P, Fontaine P, Lefebvre J, Decoulx M, Wemeau JL, Dewailly D, Rwamasirabo E, Cecat P (1986) Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery 100:1154–1162.PubMed Proye C, Fossati P, Fontaine P, Lefebvre J, Decoulx M, Wemeau JL, Dewailly D, Rwamasirabo E, Cecat P (1986) Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery 100:1154–1162.PubMed
28.
go back to reference Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers FM, Lai EW, Adams KT, Pacak K (2005) Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 90:2068–2075.CrossRef Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers FM, Lai EW, Adams KT, Pacak K (2005) Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 90:2068–2075.CrossRef
29.
go back to reference Brown MJ and Dollery CT (1981) A specific radioenzymatic assay for dihydroxyphenylalanine (DOPA). Plasma dopa may be the precursor of urine free dopamine. Br J Clin Pharmacol 11(1):79–83.CrossRef Brown MJ and Dollery CT (1981) A specific radioenzymatic assay for dihydroxyphenylalanine (DOPA). Plasma dopa may be the precursor of urine free dopamine. Br J Clin Pharmacol 11(1):79–83.CrossRef
30.
go back to reference Kang UJ, Park DH, Wessel T, Baker H and Joh TH (1992) Dopa-decarboxylation in the striata of rats with unilateral substantia nigra lesions. Neurosci Lett 147:53–57.CrossRef Kang UJ, Park DH, Wessel T, Baker H and Joh TH (1992) Dopa-decarboxylation in the striata of rats with unilateral substantia nigra lesions. Neurosci Lett 147:53–57.CrossRef
31.
go back to reference Li XM, Qi J, Juorio AV and Boulton AA (1997) Reciprocal regulation of the content of aromatic L-amino acid decarboxylase and tyrosine hydroxylase mRNA by NGF in PC12 cells. J Neurosci Res 47:449–454.CrossRef Li XM, Qi J, Juorio AV and Boulton AA (1997) Reciprocal regulation of the content of aromatic L-amino acid decarboxylase and tyrosine hydroxylase mRNA by NGF in PC12 cells. J Neurosci Res 47:449–454.CrossRef
32.
go back to reference Levi-Montalcini R and Angeletti PU (1968) Nerve growth factor. Physiol Rev 48:534–569.CrossRef Levi-Montalcini R and Angeletti PU (1968) Nerve growth factor. Physiol Rev 48:534–569.CrossRef
33.
go back to reference Herrup K and Thoenen H (1979) Properties of the nerve growth factor receptor of a clonal line of rat pheochromocytoma (PC12) cells. Exp Cell Res 121:71–78.CrossRef Herrup K and Thoenen H (1979) Properties of the nerve growth factor receptor of a clonal line of rat pheochromocytoma (PC12) cells. Exp Cell Res 121:71–78.CrossRef
34.
go back to reference Landreth GE and Shooter EM (1980) Nerve growth factor receptors on PC12 cells: ligand-induced conversion from low- to high-affinity states. Proc Natl Acad Sci U S A 77:4751–4755.CrossRef Landreth GE and Shooter EM (1980) Nerve growth factor receptors on PC12 cells: ligand-induced conversion from low- to high-affinity states. Proc Natl Acad Sci U S A 77:4751–4755.CrossRef
35.
go back to reference Middeke M, Hoffmann S, Hassan I, Wunderlich A, Hofbauer LC and Zielke A (2002) In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. Exp Clin Endocrinol Diabetes 110:386–392.CrossRef Middeke M, Hoffmann S, Hassan I, Wunderlich A, Hofbauer LC and Zielke A (2002) In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. Exp Clin Endocrinol Diabetes 110:386–392.CrossRef
36.
go back to reference Favier J, Plouin P-F, Corvol P and Gasc J-M (2002) Angiogenesis and Vascular Architecture in Pheochromocytomas. Am J Pathol 161:1235–1246.CrossRef Favier J, Plouin P-F, Corvol P and Gasc J-M (2002) Angiogenesis and Vascular Architecture in Pheochromocytomas. Am J Pathol 161:1235–1246.CrossRef
Metadata
Title
Catecholamine-Synthesizing Enzymes in Pheochromocytoma and Extraadrenal Paraganglioma
Authors
Sachiko Konosu-Fukaya
Kei Omata
Yuta Tezuka
Yoshikiyo Ono
Yayoi Aoyama
Fumitoshi Satoh
Fumiyoshi Fujishima
Hironobu Sasano
Yasuhiro Nakamura
Publication date
01-12-2018
Publisher
Springer US
Published in
Endocrine Pathology / Issue 4/2018
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-018-9544-5

Other articles of this Issue 4/2018

Endocrine Pathology 4/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.